Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $50.25M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 3.60M
Average 2.90M
Income Statement
Follow revenue through to earnings.
Revenue
$154.90M
FY 2025 · Annual
+7.4% YoYOperating Income
-$2.54M
FY 2025 · Annual
Net Income
-$20.20M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 86.35M | 107.67M | 127.04M | 144.29M | 154.9M |
| Cost of Revenue | 46.02M | 54.87M | 65.11M | 38.65M | 41.35M |
| Gross Profit | 40.33M | 52.8M | 61.94M | 105.64M | 113.56M |
| Gross Margin | 46.7% | 49.0% | 48.8% | 73.2% | 73.3% |
| Research & Development | 130.82M | 82.7M | 39.13M | 16.68M | 12.43M |
| Selling, General & Admin | 127.33M | 144.75M | 119.82M | 100.48M | 103.67M |
| Operating Expenses | 258.15M | 227.46M | 172.55M | 117.17M | 116.1M |
| Depreciation & Amortization | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| EBITDA | (215.25M) | (176.66M) | (103.79M) | (5.06M) | (17.88M) |
| EBITDA Margin | -249.3% | -164.1% | -81.7% | -3.5% | -11.5% |
| Operating Income | (217.83M) | (174.66M) | (110.62M) | (11.53M) | (2.54M) |
| Operating Margin | -252.3% | -162.2% | -87.1% | -8.0% | -1.6% |
| Interest Income | 433K | 1.64M | 3.36M | 3.55M | 0 |
| Interest Expense | 2.41M | 2.47M | 3.87M | 6.03M | 0 |
| Other Income / Expenses | (2.86M) | (7.37M) | 56K | (2.05M) | (17.66M) |
| Income Before Tax | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Pre-Tax Margin | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Net Margin | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% |
| EPS (Basic) | (2.24) | (1.67) | (0.80) | (0.09) | (0.12) |
| EPS (Diluted) | (2.24) | (1.67) | (0.80) | (0.09) | (0.12) |
| 98.47M | 109M | 138.14M | 152.45M | 166.71M | |
| 98.47M | 109M | 138.14M | 152.45M | 166.71M |
HRTX Earnings Waterfall · TTM
NASDAQ:HRTX · Revenue to Net Income
Key Ratios
Analysis
$150.7M of revenue converted into -$30.9M of net income for the selected period. Gross margin is 70.9% and net margin is -20.7%, showing how much revenue survives after costs and taxes. EPS is $-0.18, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| DEFA14A | DEFA14A filing | Nov 9, 2026 | |
| DEFA14A | DEFA14A filing | Nov 9, 2026 |
How much revenue does HRTX generate?
Heron Therapeutics, Inc. (HRTX) reported $154.90M of revenue in fiscal 2025.
Is HRTX profitable?
Heron Therapeutics, Inc. (HRTX) reported -$20.20M of net income, with a net margin of -13.0%.
Continue the stock analysis
Jump to another research area for this company.